Benjamin Besse
@benjaminbessemd.bsky.social
Medical Oncologist - Lung cancer, thymic tumors & NUT carcinomas.
Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC.
Messages reflect my own opinion.
Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC.
Messages reflect my own opinion.
Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront?
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
March 26, 2025 at 4:44 PM
Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront?
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25